ALDOSTERONE RECEPTOR ANTAGONIST AND ALPHA-ADRENERGIC MODULATING AGENT COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR CONDITIONS

摘要

A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a therapeutically-effective amount of an alpha-adrenergic modulating agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred alpha-adrenergic modulating agents are those compounds having high potency and bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha, 11alpha-substituted epoxy moiety. A preferred combination therapy includes an alpha-1-adrenergic antagonist or an alpha-2-adrenergic agonist and the aldosterone receptor antagonist epoxymexrenone.